Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22658037 | 0.93 | MAPT (0.48) | MAPTALDH1A1GAAALOX12SMN1; SMN2 | |
| SCHEMBL19019594 | 0.89 | MEN1 (0.45) | MAPTALDH1A1GAATDP1TSHR | |
| SCHEMBL18988570 | 0.83 | MEN1 (0.47) | MAPTALDH1A1TDP1MEN1KMT2A | |
| SCHEMBL19020240 | 0.83 | ALDH1A1 (0.46) | MAPTALDH1A1TDP1TSHRMAPK1 | |
| SCHEMBL18988643 | 0.82 | MEN1 (0.50) | MAPTALDH1A1SMN1; SMN2TDP1MEN1 | |
| SCHEMBL18987310 | 0.78 | KMT2A (0.47) | MAPTALDH1A1GAASMN1; SMN2TSHR | |
| SCHEMBL28697364 | 0.77 | ALDH1A1 (0.46) | MAPTALDH1A1GAAALOX12SMN1; SMN2 | |
| SCHEMBL18988650 | 0.77 | TAS1R3 (0.47) | MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL19019593 | 0.76 | TAS1R3 (0.54) | MAPTALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL18988719 | 0.76 | KMT2A (0.48) | MAPTALDH1A1TDP1MAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154104-A1 | SMALL MOLECULES FOR TREATING CANCER, INHIBITING CHEMOKINE ACTIVITY AND/OR INDUCING CELL DEATH | ALONBIO LTD. (IL) | 2025-05-15 | — | — | US | disclosed |
| EP-4524131-A1 | SMALL MOLECULES FOR TREATING CANCER, INHABITING CHEMOKINE ACTIVITY AND/OR INDUCING CELL DEATH | AlonBio Ltd. (IL) | 2025-03-19 | — | — | EP | disclosed |
| US-12202803-B2 | Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death | ALONBIO LTD. (IL) | 2025-01-21 | — | — | US | disclosed |
| EP-3759074-B1 | SMALL MOLECULES FOR TREATING CANCER, INHIBITING CHEMOKINE ACTIVITY AND/OR INDUCING CELL DEATH | ALONBIO LTD (IL) | 2025-01-01 | — | — | EP | disclosed |
| US-20240002347-A1 | SMALL MOLECULES FOR TREATING CANCER, INHIBITING CHEMOKINE ACTIVITY AND/OR INDUCING CELL DEATH | ALONBIO LTD. (IL) | 2024-01-04 | — | — | US | disclosed |
| US-11780814-B2 | Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death | ALONBIO LTD. (IL) | 2023-10-10 | — | — | US | disclosed |
| US-11780814-B2 | Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death | ALONBIO LTD. (IL) | 2023-10-10 | — | — | US | disclosed |
| US-11780814-B2 | Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death | ALONBIO LTD. (IL) | 2023-10-10 | — | — | US | disclosed |
| US-20220144777-A1 | SMALL MOLECULES FOR TREATING CANCER, INHIBITING CHEMOKINE ACTIVITY AND/OR INDUCING CELL DEATH | BIOKINE THERAPEUTICS LTD. (IL) | 2022-05-12 | — | — | US | disclosed |
| US-20220144777-A1 | SMALL MOLECULES FOR TREATING CANCER, INHIBITING CHEMOKINE ACTIVITY AND/OR INDUCING CELL DEATH | BIOKINE THERAPEUTICS LTD. (IL) | 2022-05-12 | — | — | US | disclosed |
| US-11261159-B2 | Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death | ALONBIO LTD. (IL) | 2022-03-01 | — | — | US | disclosed |
| CN-114096524-A | Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death | 阿龙拜欧有限公司 | 2022-02-25 | — | — | CN | disclosed |
| EP-3759074-A1 | SMALL MOLECULES FOR TREATING CANCER, INHIBITING CHEMOKINE ACTIVITY AND/OR INDUCING CELL DEATH | Biokine Therapeutics Ltd. (IL) | 2021-01-06 | — | — | EP | disclosed |
| US-20200369617-A1 | SMALL MOLECULES FOR TREATING CANCER, INHIBITING CHEMOKINE ACTIVITY AND/OR INDUCING CELL DEATH | BIOKINE THERAPEUTICS LTD. (IL) | 2020-11-26 | — | — | US | disclosed |
| US-20200369617-A1 | SMALL MOLECULES FOR TREATING CANCER, INHIBITING CHEMOKINE ACTIVITY AND/OR INDUCING CELL DEATH | BIOKINE THERAPEUTICS LTD. (IL) | 2020-11-26 | — | — | US | disclosed |
| WO-2020230144-A1 | SMALL MOLECULES FOR TREATING CANCER, INHIBITING CHEMOKINE ACTIVITY AND/OR INDUCING CELL DEATH | BIOKINE THERAPEUTICS LTD. (IL) | 2020-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240002347-A1 | SMALL MOLECULES FOR TREATING CANCER, INHIBITING CHEMOKINE ACTIVITY AND/OR INDUCING CELL DEATH | CCL2, CXCR2, CCL5 | MAPT 4842/4885ALDH1A1 1330/4885GAA 3240/4885 |
| US-20250154104-A1 | SMALL MOLECULES FOR TREATING CANCER, INHIBITING CHEMOKINE ACTIVITY AND/OR INDUCING CELL DEATH | CCL2, CXCR2, CCL5 | MAPT 4842/4885ALDH1A1 1330/4885GAA 3240/4885 |
| US-20220144777-A1 | SMALL MOLECULES FOR TREATING CANCER, INHIBITING CHEMOKINE ACTIVITY AND/OR INDUCING CELL DEATH | CCL2, CXCR2, CCL5 | MAPT 4842/4885ALDH1A1 1330/4885GAA 3240/4885 |
| US-20200369617-A1 | SMALL MOLECULES FOR TREATING CANCER, INHIBITING CHEMOKINE ACTIVITY AND/OR INDUCING CELL DEATH | CCL2, CXCR2, CCL5 | MAPT 4842/4885ALDH1A1 1330/4885GAA 3240/4885 |
| US-12202803-B2 | Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death | CCL2, CXCR2, CCL5 | MAPT 4842/4885ALDH1A1 1330/4885GAA 3240/4885 |
| US-11780814-B2 | Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death | CCL2, CXCR2, CCL5 | MAPT 4842/4885ALDH1A1 1330/4885GAA 3240/4885 |
| US-11261159-B2 | Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death | CCL2, CXCR2, CCL5 | MAPT 4842/4885ALDH1A1 1330/4885GAA 3240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.